查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1977777

全球糖尿病视网膜病变市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Diabetic Retinopathy Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 113 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计糖尿病视网膜病变市场将从 2025 年的 62.2 亿美元成长到 2034 年的 201.9 亿美元，2026 年至 2034 年的复合年增长率为 13.97%。

由于全球糖尿病负担日益加重，糖尿病视网膜病变市场正显着扩张。糖尿病患者人数的增加也提高了视力併发症的风险，从而推动了对有效诊断和治疗方案的需求。早期筛检计画和影像技术的进步提高了检测率，也促进了市场成长。

关键驱动因素包括抗血管内皮生长因子（VEGF）疗法、雷射治疗和外科手术的进步。人们对定期眼科检查的意识提升，以及政府为促进糖尿病管理而采取的倡议，进一步推动了市场扩张。此外，人工智慧（AI）在视网膜成像中的应用，提高了诊断的准确性和效率。

展望未来，生物製药疗法和缓释治疗方案的持续创新可望惠及市场。远距眼科服务和数位健康平台有望扩大眼科医疗服务的覆盖范围，尤其是在农村地区。随着医疗系统日益重视预防糖尿病相关併发症，预计未来几年糖尿病视网膜病变治疗的需求将稳定成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章 全球糖尿病视网膜病变市场：依类型划分

  • 市场分析、洞察与预测
  • 增殖性糖尿病视网膜病变
  • 糖尿病黄斑部水肿（DME）

第五章 全球糖尿病视网膜病变市场：依治疗类型划分

  • 市场分析、洞察与预测
  • 抗 VEGF 药物
  • 类固醇植入
  • 雷射手术
  • 玻璃体切除手术

第六章 全球糖尿病视网膜病变市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第七章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第八章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Alimera Science
    • AbbVie
    • Ampio Pharmaceuticals
    • Bayer
    • Kowa
    • Novartis
    • Pfizer
    • Regeneron Pharmaceuticals
    • F-Hoffmann-La Roche
    • Valeant Pharmaceuticals（Bausch Health Companies）
简介目录
Product Code: VMR112113274

The Diabetic Retinopathy Market size is expected to reach USD 20.19 Billion in 2034 from USD 6.22 Billion (2025) growing at a CAGR of 13.97% during 2026-2034.

The global diabetic retinopathy market is expanding significantly due to the rising global burden of diabetes. As the number of diabetic patients increases, the risk of vision-related complications is also growing, driving demand for effective diagnostic and treatment solutions. Early screening programs and improved imaging technologies have enhanced detection rates, supporting market growth.

Major drivers include advancements in anti-VEGF therapies, laser treatments, and surgical interventions. Increasing awareness about regular eye examinations and government initiatives promoting diabetes management are further strengthening market expansion. The integration of artificial intelligence in retinal imaging is also improving diagnostic accuracy and efficiency.

Looking forward, the market is expected to benefit from continued innovation in biologic therapies and long-acting treatment options. Teleophthalmology services and digital health platforms may expand access to eye care, particularly in rural areas. As healthcare systems focus on preventing diabetes-related complications, the demand for diabetic retinopathy treatments is projected to grow steadily in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Proliferative Diabetic Retinopathy
  • Diabetic Macular Edema (DME)

By Treatment Type

  • Anti VEGF Drug
  • Steroid Implants
  • Laser Surgeries
  • Vitrectomy

COMPANIES PROFILED

  • Alimera Science, AbbVie, Ampio Pharmaceuticals, Bayer, Kowa, Novartis, Pfizer, Regeneron Pharmaceuticals, FHoffmannLa Roche, Valeant Pharmaceuticals Bausch Health Companies
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL DIABETIC RETINOPATHY MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Proliferative Diabetic Retinopathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Diabetic Macular Edema (DME) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DIABETIC RETINOPATHY MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Treatment Type
  • 5.2. Anti VEGF Drug Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Steroid Implants Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Laser Surgeries Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Vitrectomy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DIABETIC RETINOPATHY MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Type
    • 6.2.2 By Treatment Type
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Type
    • 6.3.2 By Treatment Type
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Type
    • 6.4.2 By Treatment Type
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Type
    • 6.5.2 By Treatment Type
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Type
    • 6.6.2 By Treatment Type
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL DIABETIC RETINOPATHY INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Alimera Science
    • 8.2.2 AbbVie
    • 8.2.3 Ampio Pharmaceuticals
    • 8.2.4 Bayer
    • 8.2.5 Kowa
    • 8.2.6 Novartis
    • 8.2.7 Pfizer
    • 8.2.8 Regeneron Pharmaceuticals
    • 8.2.9 F-Hoffmann-La Roche
    • 8.2.10 Valeant Pharmaceuticals (Bausch Health Companies)